Viatris Inc. Common Stock VTRS

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Con 56 acciones de VTRS (USD 994,00) habrías recibido USD 26,88 en dividendos en los últimos 12 meses.

• Zacks Investment Research 5 oct

  Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?

  Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. The article highlights Viatris (VTRS) as a stock to watch with a #3 Hold rank and VGM Score of A, noting recent upward earnings estimate revisions and positive momentum.

  

• Zacks Investment Research 2 oct

  Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now?

  The WisdomTree U.S. MidCap Dividend ETF (DON) is a smart beta ETF offering exposure to mid-cap dividend-paying stocks with a 0.38% expense ratio and 2.41% dividend yield. With $3.77 billion in assets and 295 holdings, it has delivered 6.93% returns year-to-date with medium risk (beta 0.86). However, cheaper alternatives like Vanguard's VOE (0.05% expense ratio) and iShares' IWS (0.23% expense ratio) offer lower-cost options for similar market exposure.

  

• Zacks Investment Research 1 oct

  Why Viatris (VTRS) is a Top Value Stock for the Long-Term

  Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. Viatris (VTRS) is highlighted as a stock to watch with a Hold rating and attractive valuation metrics.

  

• Zacks Investment Research 31 ago

  Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris

  The generic drug industry shows mixed but resilient performance with companies focusing on operational efficiency and portfolio optimization. Three standout stocks—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through new product launches, biosimilar expansion, and complex generics development. However, the industry faces persistent pricing pressure and competition, with the Zacks Medical-Generic Drugs industry ranked #160 out of 247 industries.

  

• Zacks Investment Research 27 ago

  3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  The generic drug industry is experiencing a mixed but resilient operating environment with pricing pressures offset by healthy underlying demand and new product launches. Three companies—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through biosimilar expansion, complex generics development, and operational efficiency improvements. The industry currently trades at a valuation discount compared to broader market indices.